The results of two early-phase trials of novel lipid-lowering agents targeting ANGPTL3 and lipoprotein(a) might help to combat the residual risk of cardiovascular events in patients treated with statins and/or PCSK9 inhibitors to lower LDL-cholesterol levels.

中文翻译：

---

针对 ANGPTL3 和 Lp(a) 的新型降脂疗法

两项针对 ANGPTL3 和脂蛋白 (a) 的新型降脂药物的早期试验结果可能有助于对抗接受他汀类药物和/或 PCSK9 抑制剂治疗以降低 LDL 胆固醇水平的患者心血管事件的残余风险。